Whitehawk Therapeutics (WHWK) Stock: Buy, Sell, or Hold?
WHWK - Whitehawk Therapeutics, Inc. Common Stock
$4.11
0.04 (0.98%)
▲
5d:
-11.23%
30d:
-12.74%
90d:
+1.23%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When WHWK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: WHWK is down 11.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: WHWK is down 11.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: WHWK is currently trading at $4.11, which is considered oversold relative to its 30-day fair value range of $4.32 to $4.87.
Technical Outlook: Technically, WHWK is in a uptrend. The price is currently testing key support at $3.99. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.50 (+82.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, WHWK is in a uptrend. The price is currently testing key support at $3.99. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $7.50 (+82.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$4.32 -
$4.87
Company Quality Score
46/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (42/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 82.5% below Wall St target ($7.50)
- WARNING: Composite score 46/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.32 -
$4.87
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$3.99
Resistance Level
$5.03
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.17
Wall Street Target
$7.50
(+82.5%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: September 13, 2026 11:21 AM ET
Data refreshes hourly during market hours. Next update: 12:21 PM
Data refreshes hourly during market hours. Next update: 12:21 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is WHWK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Scott M Giacobello
SELL
141600 shares
2026-04-16
Scott M Giacobello
SELL
77000 shares
2026-04-15
Bryan Ball
SELL
92460 shares
2026-04-14
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 54 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 52 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |